Literature DB >> 1327596

Comparison of the pharmacokinetics and pharmacodynamics of perindopril, cilazapril and enalapril.

W J Louis1, E L Conway, H Krum, B Workman, O H Drummer, W Lam, P Phillips, L G Howes, B Jackson.   

Abstract

1. The pharmacokinetic and pharmacodynamic responses to enalapril, perindopril and cilazapril have been studied in essential hypertensives (2, 4 and 8 mg perindopril and 2.5 mg cilazapril, single dose and steady state) and normotensive volunteers (10 mg enalapril, single dose). 2. Plasma levels of the active diacid compounds reached similar peaks after single dose administration of the drugs. However, perindoprilat levels persisted for 5 days whereas cilazaprilat levels were not detectable beyond 12 h. 3. The higher levels of perindoprilat were associated with a greater inhibition of plasma angiotensin-converting enzyme (ACE) activity in both acute and steady state studies. 4. The potency of the active diacids in inhibiting plasma ACE activity was perindoprilat greater than cilazaprilat greater than enalaprilat. 5. There was a close relationship between plasma concentration, ACE inhibition and blood pressure decrease. Although both cilazapril and perindopril administration reduced blood pressure in hypertensive subjects, only perindopril exerted 24 h blood pressure control at the doses used.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1327596     DOI: 10.1111/j.1440-1681.1992.tb02811.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol Suppl        ISSN: 0143-9294


  6 in total

Review 1.  Perindopril: an updated review of its use in hypertension.

Authors:  M Hurst; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based study.

Authors:  Richard Ian Ogilvie; Sanjiv Anand; Pierre Roy; Selwyn De Souza
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 3.  Choosing the right ACE inhibitor. A guide to selection.

Authors:  G Leonetti; C Cuspidi
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

Review 4.  RAAS inhibition and mortality in hypertension.

Authors:  Roberto Ferrari
Journal:  Glob Cardiol Sci Pract       Date:  2013-11-01

5.  Comparative Solid-State Stability of Perindopril Active Substance vs. Pharmaceutical Formulation.

Authors:  Valentina Buda; Minodora Andor; Adriana Ledeti; Ionut Ledeti; Gabriela Vlase; Titus Vlase; Carmen Cristescu; Mirela Voicu; Liana Suciu; Mirela Cleopatra Tomescu
Journal:  Int J Mol Sci       Date:  2017-01-15       Impact factor: 5.923

6.  Perindopril Induces TSP-1 Expression in Hypertensive Patients with Endothelial Dysfunction in Chronic Treatment.

Authors:  Valentina Buda; Minodora Andor; Lucian Petrescu; Carmen Cristescu; Dana Emilia Baibata; Mirela Voicu; Melania Munteanu; Ioana Citu; Calin Muntean; Octavian Cretu; Mirela Cleopatra Tomescu
Journal:  Int J Mol Sci       Date:  2017-02-07       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.